{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:26Z","timestamp":1792088066929,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.03.015","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T14:40:17Z","timestamp":1651156817000},"page":"20-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study"],"prefix":"10.1016","volume":"169","author":[{"given":"S.P.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Klaase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bezemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Krimpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van der Breggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.","family":"Wismans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.M.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Vroman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stadhouders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.F.C.C.","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Luider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.015_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.015_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.015_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pan.2015.09.008","article-title":"Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study","volume":"15","author":"Matsumoto","year":"2015","journal-title":"Pancreatology"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.015_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamasurg.2015.0668","article-title":"Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma","volume":"150","author":"Paniccia","year":"2015","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.015_bib6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/SLA.0b013e3181613142","article-title":"Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?","volume":"247","author":"Schnelldorfer","year":"2008","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12957-016-1078-z","article-title":"Preoperative predictors for early recurrence of resectable pancreatic cancer","volume":"15","author":"Nishio","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2022.03.015_bib8","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.03.015_bib9","first-page":"JCO2102233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10073","key":"10.1016\/j.ejca.2022.03.015_bib10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ejca.2022.03.015_bib11","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.015_bib12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"issue":"19","key":"10.1016\/j.ejca.2022.03.015_bib13","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.03.015_bib14","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1200\/JCO.2016.34.15_suppl.3092","article-title":"Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer","volume":"34","author":"Nesselhut","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.015_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.015_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"15_Suppl.","key":"10.1016\/j.ejca.2022.03.015_bib18","first-page":"4622","article-title":"A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS)","volume":"38","author":"Brandon George","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O'Hara","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.015_bib20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nature Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","article-title":"Exclusion of T Cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4\/80(+) extratumoral macrophages","volume":"149","author":"Beatty","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.015_bib22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.015_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","article-title":"Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer","volume":"37","author":"Hegde","year":"2020","journal-title":"Cancer Cell"},{"issue":"B","key":"10.1016\/j.ejca.2022.03.015_bib24","first-page":"955","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.015_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1084\/jem.20031435","article-title":"Mesothelin-specific CD8(+) T cell responses provide evidence of in\u00a0vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients","volume":"200","author":"Thomas","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2022.03.015_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1479-5876-12-175","article-title":"Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer","volume":"12","author":"Shindo","year":"2014","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.015_bib27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00262-004-0540-x","article-title":"Escape from immunotherapy: possible mechanisms that influence tumor regression\/progression","volume":"53","author":"Ahmad","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.03.015_bib28","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol Cell Proteom"},{"issue":"34","key":"10.1016\/j.ejca.2022.03.015_bib29","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.03.015_bib30","first-page":"3715","article-title":"Immunohistochemical analysis of WT1 antigen expression in various solid cancer cells","volume":"36","author":"Naitoh","year":"2016","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.015_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000772","article-title":"Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model","volume":"8","author":"Lau","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.03.015_bib33","series-title":"Desmoplasia and chemoresistance in pancreatic cancer","author":"Whatcott","year":"2012"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.015_bib34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.coi.2005.01.004","article-title":"Migration of dendritic cell based cancer vaccines: in\u00a0vivo veritas?","volume":"17","author":"Adema","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.015_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.03.015_bib37","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3389\/fimmu.2018.02034","article-title":"Autologous dendritic cell therapy in mesothelioma patients enhances frequencies of peripheral CD4 T cells expressing HLA-DR, PD-1, or ICOS","volume":"9","author":"de Goeje","year":"2018","journal-title":"Front Immunol"},{"issue":"19","key":"10.1016\/j.ejca.2022.03.015_bib38","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.015_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1084\/jem.20011558","article-title":"Differential T cell function and fate in lymph node and nonlymphoid tissues","volume":"195","author":"Harris","year":"2002","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4049\/jimmunol.170.1.28","article-title":"Cutting edge: L-selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen","volume":"170","author":"Hengel","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.015_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.015_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007066","article-title":"Jak3 is involved in dendritic cell maturation and CCR7-dependent migration","volume":"4","author":"Rivas-Caicedo","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen Daniel","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.015_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1189\/jlb.4MR1116-466R","article-title":"Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies","volume":"102","author":"Keirsse","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.immuni.2017.12.014","article-title":"Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c(+)CD103(+) monocytic antigen-presenting cells in tumors","volume":"48","author":"Sharma","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.ejca.2022.03.015_bib46","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1245\/s10434-020-08235-w","article-title":"Conditional survival after resection for pancreatic cancer: a population-based study and prediction model","volume":"27","author":"Latenstein","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.015_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"npj Vaccines"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.015_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer \u2013 clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:01Z","timestamp":1760733301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":48,"alternative-id":["S0959804922001599"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}